About Prosarix
Prosarix is a Healthcare company based in Cambridge (United Kingdom) founded in 2006, and was acquired by RxCelerate in February 2019. Computational drug discovery company with proprietary platform for small molecule screening and design. Prosarix offers products and services including ProtoDiscoveryâ„¢ Platform, RxNfinityâ„¢, and Virtual Screening. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is PROSARIX UK LTD. Its competitors include Inpharmatica, C4X Discovery and PostEra; 1 of its 3 listed competitors has raised funding.
Company details
Prosarix Ltd is a UK-based computational drug discovery company with a proprietary platform for drug screening and design. Their proprietary ProtoDiscovery platformsuite can be used for the identification and optimisation of small molecule ligands to specific targets. The suite contains three structure-based technologies namely ProtoScore(Proprietary Scoring function), ProtoScreen(for virtual screening), ProtoBuild (Small molecule de novo design tool) and two ligand-based technologies. ProtoShapeES (Electrostatic and molecule shape-based screening), ProtoClassify (Ligand classification using pharmacophore features). The company also has ProtoDiscovery Compound Database (PCD), which has a library of gt;5M compounds for screening. The company also offers EnzaCore SAR Explorer Panels, a set of products that can be used for the incorporation of chiral building blocks. Prosarix has an in-house discovery program focused on GPCR targets to identify and develop novel lead series for CNS. Prosarix claims that its advanced lead candidates from its in-house program have shown pre-clinical efficacy in models of pain, anxiety and depression. Prosarix was formed in 2007 following the acquisition of the platform from Amura Holdings.
- Headquarters Cambridge, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website prosarix.com
- Social LinkedIn YouTube
- Acquired by RxCelerate (Feb 2019)
- Legal Name Prosarix Uk Ltd
- InvestorsEvolva
& 1 more
- Acquired by
Products & Services of Prosarix
Prosarix offers a comprehensive portfolio of products and services, including ProtoDiscovery™ Platform, RxNfinity™, and Virtual Screening.
Facilitates rapid identification and optimization of small molecules and biologics.
Explores vast chemical spaces for novel compound identification.
Screens compounds for potential drug targets efficiently.
Apps and channels of Prosarix
its YouTube channel RxCelerate has 45 subscribers and 5 videos.
Videos from Prosarix
The most watched videos on Prosarix's YouTube channel, RxCelerate (45 subscribers). Click a video to play it here.
More on RxCelerate.
Investors in Prosarix
Prosarix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Evolva and RxCelerate.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pre-clinical contract research services are offered for drug candidates. | 2012 | rxcelerate.com | Babraham, United Kingdom | |
Producer of natural and functional ingredients for food, beverage and healthcare products | 2004 | evolva.com | Reinach, Switzerland |
Investor details for Prosarix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Prosarix
3 dated milestones of Prosarix across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Prosarix is founded.
- Exit Acquired by Evolva.
- Exit Acquired by RxCelerate.
Competitors of Prosarix
Prosarix has 3 listed competitors in our database, 1 of them funded. They include Inpharmatica, C4X Discovery and PostEra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inpharmatica.co.uk | 1998 | London, United Kingdom | 62 | Developer of predictive informatics based platform for drug discovery | ||
| c4xdiscovery.com | 2008 | Manchester, United Kingdom | 46 | Developer of optimized drug discovery and design services | ||
| postera.ai | 2019 | London, United Kingdom | $26.2M | 3 | AI based molecular designing software for drug discovery |
Detailed competitors of Prosarix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Prosarix
Websites that share an audience with Prosarix (prosarix.com).
Websites whose visitors overlap most with Prosarix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Prosarix (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prosarix
Complete news archive for Prosarix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prosarix
Prosarix was founded in 2006.
Prosarix is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Prosarix Ltd is a UK-based computational drug discovery company with a proprietary platform for drug screening and design. Their proprietary ProtoDiscovery platformsuite can be used for the identification and optimisation of small molecule ligands to specific targets. The suite contains three structure-based technologies namely ProtoScore(Proprietary Scoring function), ProtoScreen(for virtual screening), ProtoBuild (Small molecule de novo design tool) and two ligand-based technologies. ProtoShapeES (Electrostatic and molecule shape-based screening), ProtoClassify (Ligand classification using pharmacophore features). The company also has ProtoDiscovery Compound Database (PCD), which has a library of gt;5M compounds for screening. The company also offers EnzaCore SAR Explorer Panels, a set of products that can be used for the incorporation of chiral building blocks. Prosarix has an in-house discovery program focused on GPCR targets to identify and develop novel lead series for CNS. Prosarix claims that its advanced lead candidates from its in-house program have shown pre-clinical efficacy in models of pain, anxiety and depression. Prosarix was formed in 2007 following the acquisition of the platform from Amura Holdings.
Prosarix's top competitors include PostEra, Inpharmatica and C4X Discovery.
Prosarix offers ProtoDiscoveryâ„¢ Platform, RxNfinityâ„¢, and Virtual Screening.
Prosarix has 2 investors. Key investors include Evolva, and RxCelerate.
Prosarix operates through Prosarix Uk Ltd.
Yes. Prosarix was acquired by RxCelerate in February 2019.